Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | SMPD1 | P17405 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29651387 | 0.98 | BLM (1.00) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| Hydrochloric Acid SCHEMBL7194533 | 0.98 | BLM (1.00) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL18239557 | 0.95 | CYP3A4 (0.90) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL7290182 | 0.93 | CYP1A2 (0.87) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL6575808 | 0.92 | CYP3A4 (0.84) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL6574463 | 0.92 | CYP3A4 (0.84) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL27856807 | 0.92 | CYP3A4 (0.84) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL8828336 | 0.92 | CYP3A4 (0.84) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL6575575 | 0.91 | CYP1A2 (0.83) | CYP1A2CYP3A4CYP2D6BLMPMP22 | |
| SCHEMBL2770457 | 0.90 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2D6BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270693-A1 | Molecular Targets for Modulation of Dissociative and Associative States | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-08-31 | — | — | US | claimed |
| WO-2022035773-A1 | MOLECULAR TARGETS FOR MODULATION OF DISSOCIATIVE AND ASSOCIATIVE STATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-17 | — | — | WO | claimed |
| US-4956389-A | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS WITH N-METHYL-N-BIS(3,4-DIMETHOXYPHENYLETHYL)AMINE | YASON S.R.L. (IT) | 1990-09-11 | — | — | US | claimed |
| US-12582616-B2 | Molecular targets for modulation of dissociative and associative states | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CHILDREN'S MEDICAL CENTER CORPORATION | 2025-04-22 | — | — | US | disclosed |
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |
| US-20240091238-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230270693-A1 | Molecular Targets for Modulation of Dissociative and Associative States | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220152041-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2022035773-A1 | MOLECULAR TARGETS FOR MODULATION OF DISSOCIATIVE AND ASSOCIATIVE STATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-17 | — | — | WO | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-1998004250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE REVERSION OF MULTIPLE RESISTANCE TO DRUGS | CONSULTANTS INTERNATIONAUX SUR LE MEDICAMENT (S.A.R.L.) (FR) | 1998-02-05 | — | — | WO | disclosed |
| WO-1998004250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE REVERSION OF MULTIPLE RESISTANCE TO DRUGS | CONSULTANTS INTERNATIONAUX SUR LE MEDICAMENT (S.A.R.L.) (FR) | 1998-02-05 | — | — | WO | disclosed |
| US-4956389-A | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS WITH N-METHYL-N-BIS(3,4-DIMETHOXYPHENYLETHYL)AMINE | YASON S.R.L. (IT) | 1990-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | CYP1A2 4732/4885CYP3A4 3746/4885CYP2D6 4323/4885 |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | CYP1A2 4732/4885CYP3A4 4816/4885CYP2D6 4813/4885 |
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CALM1, RACK1, RRBP1 | CYP1A2 4636/4885CYP3A4 4828/4885CYP2D6 4722/4885 |
| US-12582616-B2 | Molecular targets for modulation of dissociative and associative states | FABP7, NCS1, GAP43 | CYP1A2 4554/4885CYP3A4 4157/4885CYP2D6 3028/4885 |
| US-20240091238-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | CYP1A2 4616/4885CYP3A4 4827/4885CYP2D6 4709/4885 |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | CYP1A2 4616/4885CYP3A4 4827/4885CYP2D6 4709/4885 |
| US-20220152041-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CALM1, RACK1, RRBP1 | CYP1A2 4636/4885CYP3A4 4828/4885CYP2D6 4722/4885 |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CALM1, RACK1, CAMK2B | CYP1A2 4616/4885CYP3A4 4827/4885CYP2D6 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.